The goal of this collaborative was to examine the contributing factors towards the failure of late-stage clinical product development and develop key considerations for stakeholders to improve the ...

This article summarizes a discussion at LSX Biopharm America on September 11. A panel of industry experts discussed approaches to overcoming the most urgent CMC challenges during the discussion. The ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...

By Kamal Choudhury May 14 (Reuters) - Biogen said on Thursday it would move its experimental Alzheimer's drug into late-stage ...

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

Despite decades of progress in pharmaceutical R&D, the earliest phase of drug discovery—where molecules are conceived and designed—remains costly, inefficient, and burdened by high failure rates. Most ...

An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...

The Russian Ministry of Industry and Trade has decided to limit funding for the development of innovative drugs amid a ...